PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 68.68

Change

-0.46 (-0.67)%

Market Cap

N/A

Volume

4.47K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-04 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.97 (-0.66%)

USD 40.26B
FHLC Fidelity® MSCI Health Care In..

-0.43 (-0.61%)

USD 2.86B
FXH First Trust Health Care AlphaD..

-0.16 (-0.15%)

USD 1.18B
XHE SPDR® S&P Health Care Equipme..

+1.18 (+1.33%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.06 (+0.24%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.28 (+0.73%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-0.35 (-0.37%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.35 (+1.23%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.26 (-0.40%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.45 (+1.56%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.31% 52% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.31% 52% F 48% F
Trailing 12 Months  
Capital Gain 23.38% 76% C+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.38% 76% C+ 68% D+
Trailing 5 Years  
Capital Gain 36.73% 71% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.73% 71% C- 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.11% 52% F 57% F
Dividend Return 6.13% 48% F 50% F
Total Return 0.01% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 21.03% 43% F 51% F
Risk Adjusted Return 29.13% 52% F 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.